Hui‐Chuan Sun - Concepedia

Author

Hui‐Chuan Sun

Fudan University ORCID

Also Known As

H C Sun, H Sun, H-C Sun, H-C. Sun, H. Sun, H.-C. Sun, HC Sun, Haibing Sun, Haidong Sun, HaoyuHaoyu Sun

527

Publications

21.6K

Citations

H-Index

122

Concepts

All Affiliations

Fudan University Zhongshan Hospital Sun Yat-sen University The First Affiliated Hospital, Sun Yat-sen University Fudan University Shanghai Cancer Center

About

Hui‐Chuan Sun is an author at Fudan University specializing in medicine, hepatocellular carcinoma, and hepatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	71	6.5K
2	Health Sciences	18	20	1.4K
3	Engineering	4	4	176
4	Education	1	1	15
5	Natural Sciences	1	1	94

Hui‐Chuan Sun

220

Publications

19.7K

Citations

H-Index

Page 1

	Year	Citations
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma Ying Jiang, Aihua Sun, Yang Zhao, Nature Hepatocellular CarcinomaMedicineEarly-stage Hepatocellular CarcinomaLiver CancerProteomics	2019	925
Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma Yun‐Fan Sun, Liang Wu, Yu Zhong, Cell HepatologyTumor MicroenvironmentPathologyLiver CancerSingle-cell Landscape	2020	894
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition) Jian Zhou, Hui‐Chuan Sun, Zheng Wang, Liver Cancer	2020	813
MicroRNA Expression, Survival, and Response to Interferon in Liver Cancer Junfang Ji, Jiong Shi, Anuradha Budhu, New England Journal of Medicine	2009	804
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition) Jian Zhou, Hui‐Chuan Sun, Zheng Wang, Liver Cancer	2018	681
Plasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular Carcinoma Jian Zhou, Lei Yu, Xue Gao, Journal of Clinical Oncology	2011	637
High Expression of Macrophage Colony-Stimulating Factor in Peritumoral Liver Tissue Is Associated With Poor Survival After Curative Resection of Hepatocellular Carcinoma Xiao‐Dong Zhu, Jubo Zhang, Peng–Yuan Zhuang, Journal of Clinical Oncology	2008	549
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial Shukui Qin, Minshan Chen, Ann‐Lii Cheng, The Lancet Surgical OncologyHepatologyMedicinePathologyHigh-risk Hepatocellular Carcinoma	2023	415
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition) Jian Zhou, Hui‐Chuan Sun, Zheng Wang, Liver Cancer	2023	389
Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects Wei Zhang, Xiao‐Dong Zhu, Hui‐Chuan Sun, Clinical Cancer Research	2010	370

Page 1